Apremilast attenuates hepatic steatosis and metabolic dysfunction in a murine model of MASLD: Implications for patients with Psoriatic disease
Apremilast ameliorates hepatic dysfunction, improves insulin sensitivity, and reduces systemic metabolic dysfunction in a murine MASLD model. These findings support its therapeutic potential in PsD patients with metabolic disease, offering both anti-inflammatory and metabolic benefits.
Authors
- A. Llamas-Urbano
- E. Martin-Salazar (ORCID: https://orcid.org/0000-0001-5886-9030)
- Sergio Rodríguez‐Cuenca (ORCID: https://orcid.org/0000-0001-9635-0504)
- Clementina López‐Medina (ORCID: https://orcid.org/0000-0002-2309-5837)
- Julio M. Martínez‐Moreno (ORCID: https://orcid.org/0000-0002-1945-5078)
- Antonio Vidal‐Puig (ORCID: https://orcid.org/0000-0003-4220-9577)
- M. Ruiz-Ponce (ORCID: https://orcid.org/0000-0001-8713-7760)
- Nuria Barbarroja (ORCID: https://orcid.org/0000-0002-0962-6072)
- Eduardo Collantes‐Estévez (ORCID: https://orcid.org/0000-0002-7647-6289)
- C. Pérez‐Sánchez (ORCID: https://orcid.org/0000-0002-1903-5970)
- L. Cuesta-López (ORCID: https://orcid.org/0000-0003-1450-8131)
- C. López-Pedrera (ORCID: https://orcid.org/0000-0003-2067-4603)
- I. Arias de la Rosa (ORCID: https://orcid.org/0000-0002-1145-4935)
- Pedro Ortiz-Buitrago
- Mark Campbell
- Alejandro Escudero-Contreras
- María Dolores López-Montilla
- Antonio Manuel Barranco (ORCID: https://orcid.org/0009-0008-2142-284X)
- Laura Romero-Zurita
Institutions
- Instituto Maimónides de Investigación Biomédica de Córdoba (ES)
- Hospital General de Tomelloso (ES)
- Wellcome/MRC Institute of Metabolic Science (GB)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1016/j.biopha.2025.118757
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00